Diabetes: Why Not All Muscle Loss Looks the Same

Sarcopenia — the age-related loss of muscle mass and strength — isn’t one condition with one risk profile. A new study of frail older adults with diabetes found two genuinely different versions of it, and each comes with its own set of complications worth watching for.^[1]

Two versions of the same diagnosis

Researchers studied 109 adults aged 70 and older who were living with both diabetes and frailty. Using standard diagnostic criteria (the European Working Group on Sarcopenia in Older People, or EWGSOP2), they found sarcopenia in nearly 79% of participants — and then split those cases into phenotypes based on body composition: how much muscle versus fat each person carried.

Two clear patterns emerged. Sarcopenic obesity — low muscle mass combined with high body fat — clustered with classic insulin-resistance markers: more central (abdominal) fat, higher triglycerides, a higher triglyceride-glucose index (a marker of insulin resistance), universal metabolic syndrome, and greater insulin dosing needs. Sarcopenia without excess adiposity — low muscle mass without the extra fat — looked different: more nerve damage (neuropathy), more kidney involvement (albuminuria), more cerebrovascular disease, and worse continuous glucose monitor (CGM) readings, despite having similar average blood sugar (HbA1c) numbers to the other group.

That last point is the one worth sitting with: two people can have an identical HbA1c on a standard lab panel and still be living with very different day-to-day glucose control and very different complication risk, depending on their muscle-and-fat phenotype.

What the data can (and can’t) tell us

This was a cross-sectional study of 109 people at one point in time — a real, useful signal, not a definitive map. In the researchers’ own statistical modeling, HbA1c itself was the only factor that independently predicted poor glucose control (time in target range below 70%); phenotype alone didn’t reach statistical significance once other factors were accounted for. The authors are explicit that these are preliminary findings needing confirmation in larger, longer studies. What’s genuinely new here is the descriptive picture: sarcopenia in diabetes isn’t a single entity, and the “thin frail” version carries a distinct complication pattern from the “sarcopenic obesity” version.

What this means for you

If you or someone you’re caring for is older, living with diabetes, and noticeably losing strength or muscle:

• Don’t assume a normal HbA1c means glucose control is fine. If a continuous glucose monitor is an option, it can reveal patterns a quarterly A1c check misses entirely — this was exactly the gap this study flagged for the leaner sarcopenic group.
• Track body composition, not just weight or BMI. “Thin” and “healthy” aren’t synonyms in older adults with diabetes — low muscle mass without excess fat carried its own distinct risk pattern here, including nerve and vascular complications.
• Bring muscle mass into diabetes management conversations. Ask your care team whether a body composition assessment (even a simple bioelectrical impedance scale) makes sense alongside routine diabetes monitoring, especially if strength or mobility has changed recently.

Diabetes and muscle loss are frequently managed as separate problems. This study is a reminder that in older adults, they’re often the same problem wearing different faces.

References

1. Guevara E, Simó-Servat A, Perea V, et al. “Body composition-defined sarcopenia phenotypes, diabetes complications, and CGM-derived glycemic profiles in frail older adults with diabetes: a cross-sectional study.” The Journal of Nutrition, Health & Aging, 2026;30(10):100947. Finding used: among 109 adults aged 70+ with diabetes and frailty, sarcopenic obesity clustered with insulin-resistance markers (central adiposity, higher triglycerides, universal metabolic syndrome), while sarcopenia without adiposity clustered with more neuropathy, albuminuria, cerebrovascular disease, and lower CGM time-in-range despite similar HbA1c; HbA1c, not phenotype, was the only independent correlate of poor glycemic control in adjusted models. DOI: 10.1016/j.jnha.2026.100947. Source: PubMed 42570512. ↑︎

Kurt Greiner

Kurt is a digital strategist and IT professional blending emerging technology with practical application to help businesses and individuals streamline their digital presence. His current work focuses on the intersection of intentional living and technological resilience, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.